Literature DB >> 21847060

Recommendations for uniform definitions of surgical techniques for malignant pleural mesothelioma: a consensus report of the international association for the study of lung cancer international staging committee and the international mesothelioma interest group.

David Rice1, Valerie Rusch, Harvey Pass, Hisao Asamura, Takashi Nakano, John Edwards, Dorothy J Giroux, Seiki Hasegawa, Kemp H Kernstine, David Waller, Ramon Rami-Porta.   

Abstract

INTRODUCTION: Extrapleural pneumonectomy has been well defined; however, surgeons vary regarding the surgical extent and goals of "pleurectomy/decortication" (P/D). We explored mesothelioma surgeons' concepts of P/D with the aim of unifying surgical nomenclature.
METHODS: A web-based survey was administered to surgeons who operated on malignant pleural mesothelioma (MPM) for diagnosis, staging, palliation, or cytoreduction. One hundred thirty surgeons from 59 medical centers were included. Surgeons who did not perform surgery for MPM within the last year were excluded.
RESULTS: There were 62 (48%) respondents from 39 medical centers in 14 countries. The mean number of patients with MPM seen annually at each medical center was 46, and the mean annual number of cytoreductive procedures performed per surgeon was 8. Most (88%) agreed that the goal of cytoreductive surgery should be macroscopic complete resection of tumor. P/D was defined as resection of parietal and visceral pleura with the aim of achieving macroscopic complete resection by 72% of respondents. If the diaphragm or pericardium required resection, 64% preferred the term "radical P/D," whereas "P/D" (40%) or "total pleurectomy" (39%) was preferred if these structures were not removed. Most surgeons believed that extrapleural pneumonectomy (90%) or "radical P/D" (68%) could provide adequate cytoreduction, whereas only 23% thought that P/D could.
CONCLUSIONS: There was significant variation regarding surgical nomenclature for procedures for MPM. The International Staging Committee of the International Association for the Study of Lung Cancer and the International Mesothelioma Interest Group recommend that P/D should aim to remove all macroscopic tumor involving the parietal and visceral pleura and should be termed "extended" P/D when the diaphragm or pericardium is resected.

Entities:  

Mesh:

Year:  2011        PMID: 21847060     DOI: 10.1097/JTO.0b013e3182208e3f

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN: 1556-0864            Impact factor:   15.609


  65 in total

1.  Radical surgery for malignant pleural mesothelioma: have we identified the appropriate selection tools?

Authors:  Nico van Zandwijk; Glen Reid; Anthony Linton; Steven Kao
Journal:  Ann Cardiothorac Surg       Date:  2012-11

2.  Standardizing surgical treatment in malignant pleural mesothelioma.

Authors:  David Rice
Journal:  Ann Cardiothorac Surg       Date:  2012-11

3.  Extrapleural pneumonectomy and extended pleurectomy/decortication for malignant pleural mesothelioma: the Memorial Sloan-Kettering Cancer Center approach.

Authors:  Valerie W Rusch
Journal:  Ann Cardiothorac Surg       Date:  2012-11

4.  Radical pleurectomy and photodynamic therapy for malignant pleural mesothelioma.

Authors:  Joseph S Friedberg
Journal:  Ann Cardiothorac Surg       Date:  2012-11

5.  Video-atlas of radical pleurectomy for malignant pleural mesothelioma.

Authors:  Servet Bölükbas; Michael Eberlein; Joachim Schirren
Journal:  Ann Cardiothorac Surg       Date:  2012-11

6.  Surgical therapeutic options.

Authors:  Servet Bölükbas; Joachim Schirren
Journal:  Dtsch Arztebl Int       Date:  2013-09       Impact factor: 5.594

7.  Current issues in malignant pleural mesothelioma evaluation and management.

Authors:  Jing Ai; James P Stevenson
Journal:  Oncologist       Date:  2014-07-24

Review 8.  [Surgical therapy of malignant pleural mesothelioma].

Authors:  M Schirren; S Sponholz; S Oguzhan; A Fisseler-Eckhoff; A Fischer; J Schirren
Journal:  Chirurg       Date:  2016-05       Impact factor: 0.955

Review 9.  Photodynamic therapy for lung cancer and malignant pleural mesothelioma.

Authors:  Charles B Simone; Keith A Cengel
Journal:  Semin Oncol       Date:  2014-10-07       Impact factor: 4.929

10.  Validation of EORTC and CALGB prognostic models in surgical patients submitted to diagnostic, palliative or curative surgery for malignant pleural mesothelioma.

Authors:  Alberto Sandri; Francesco Guerrera; Matteo Roffinella; Stefania Olivetti; Lorena Costardi; Alberto Oliaro; Pier Luigi Filosso; Paolo Olivo Lausi; Enrico Ruffini
Journal:  J Thorac Dis       Date:  2016-08       Impact factor: 2.895

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.